Drug intelligence / Profile preview

bee venom immunotherapy + Advax

Development stage: Unknown
Lead developer: Vaxine
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Bee venom immunotherapy + Advax is an investigational allergen immunotherapy developed by Vaxine Pty Ltd for the treatment of bee venom allergy, specifically targeting anaphylaxis from European honeybee stings. The product consists of honeybee venom allergens combined with Advax, a novel noninflammatory polysaccharide adjuvant derived from delta inulin, which was developed through the NIH's Adjuvant Development Program. The therapy is designed to modulate the immune system's IgE/IgG4 axis by suppressing the allergic (TH2/IgE) response and promoting a protective IgG4 response to bee venom allergens. In a single-centre, randomized controlled Phase 1/2 trial involving 27 adults, the Advax-adjuvanted regimen was well tolerated and demonstrated enhanced and more durable IgG4 immunogenicity compared to standard venom immunotherapy alone.

Other names: Advax-adjuvanted honeybee venom immunotherapyAdvax-adjuvanted HBVITAdvax-adjuvanted bee venom desensitisation

Targets

CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)Honey bee venom allergens

Beyond the preview

Go deeper on bee venom immunotherapy + Advax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bee venom immunotherapy + Advax.

Explore the full profile